GNIPST BULLETIN 2017

06-01-2017

06th January, 2017

Volume No.: 62

Issue No.: 04

Vision
To develop responsible citizens who would be professionally equipped to think globally and act
locally and become reformers of society to meet the challenges of future.
Mission
To impart high quality pharmaceutical science, technology and management education to the budding
professionals and provide the ambience needed for developing requisite skills to make a mark of
excellence in Education, Research, Business , Industry and achieve highest personal standards.
Contents
Message from PRINCIPAL
Editorial board
Historical article
News Update
Knowledge based Article
Disease Related Breaking News
Upcoming Events
Drugs Update
Campus News
Students Section
Editors Note

Archive

GNIPST Photo Gallery

For your comments/contribution

OR For Back-Issues,
mailto:gnipstbulletin@gmail.com

GURU NANAK INSTITUTE OF PHARMACEUTICAL

SCIENCE AND TECHNOLOGY
Website: http://gnipst.ac.in

06-01-2017

MESSAGE FROM PRINCIPAL

"It can happen. It does happen.

But it can't happen if you quit." Lauren Dane.

We are what we repeatedly do.

Excellence then is not an act, but a habit. Aristotle

It gives me immense pleasure to pen a few words for our e-bulletin. At the onset I would like to thank the
last years editors and congratulate the newly selected editors for the current year.
Our first consideration is always in the best interest of the students. Our goal is to promote academic
excellence and continuous improvement.
I believe that excellence in education is aided by creating a learning environment in which all learners are
supported in maximizing their potential and talents. Education needs to focus on personalized learning
and instruction, while promoting an education system that is impartial, universally accessible, and meeting
the needs of all students.
It is of paramount importance that our learners have sufficient motivation and encouragement in order to
achieve their aims. We are all very proud of you, our students, and your accomplishments and look
forward to watching as you put your mark on the profession in the years ahead.
The call of the time is to progress, not merely to move ahead. Our progressive Management is looking
forward and wants our Institute to flourish as a Post Graduate Institute of Excellence. Steps are taken in
this direction and fruits of these efforts will be received by our students in the near future. Our Teachers
are committed and dedicated for the development of the institution by imparting their knowledge and play
the role of facilitator as well as role model to our students.
The Pharmacy profession is thriving with a multitude of possibilities, opportunities and positive
challenges. At Guru Nanak Institute of Pharmaceutical Science and Technology, our focus is on holistic
needs of our students.
I am confident that the students of GNIPST will recognize all the possibilities, take full advantage of the
opportunities and meet the challenges with purpose and determination.
Excellence in Education is not a final destination, it is a continuous walk. I welcome you to join us on
this path.
My best wishes to all.
Dr. A. Sengupta

Click here to go at the top

1

06-01-2017

EDITORIAL BOARD
CHIEF EDITOR
EDITOR
ASSOCIATE EDITOR

DR. ABHIJIT SENGUPTA

MS. JEENATARA BEGUM
MR.
DIPANJAN
MANDAL

HISTORICAL ARTICLE

William Buckland

William Buckland is more properly known as the Rev. Dr. William

Buckland. He was a theologian hailing from England and later on
he became the dean of none other than Westminster. Apart from
his career and service as a well-respected theologian, he was not
just a man of God but a man of science as well. He had been a
palaeontologist and geologist, and these fields of specialization
lead to his detailed documentation of the dinosaur fossil now
known as the megalosaurus. He had been a proponent of what is
known as the Gap Theory which was, in a way, a theory that
reconciled biblical accounts of creation with the scientific
discoveries made by modern man.
Early Life and Educational Background
He was born in Axminster, Devon, on the 12th of March in 1784. He
was the eldest son of then Rector of Templeton and Trusham
Charles Buckland, and Elizabeth Buckland. It is said that William
Bucklands interest in fossils had been tapped by his birthplaces
proximity to quarries in Axminster which was then bountiful with
fossil remains. His father had a keen interest in the development of
roads and William Buckland was often taken on trips near the
quarries which is why he had become so familiar with such scenes.
Initially, he had been home schooled and it was his father who had
been teaching him. In 1797, however, he was entered to Blundells
school which was in Tiverton to receive a more comprehensive
education which would prepare him for his days in the university.
A year after his time in Blundells, he was moved to St. Marys
College in Winchester where he was able to progress academically
Click here to go at the top
2

06-01-2017

while still being able to retain his love for natural science and
history.
After some coaching from his uncle, William Buckland won a
scholarship to Corpus Christi College in 1801, and this was where
he began his Oxford career. Three years later, he had obtained his
BA degree through his scholarship and had also taken pupils to
teach. He had never neglected his studies, but he was also able to
make time for furthering his knowledge on scientific matters by
attending lectures on geology given by John Kidd, as well as
anatomy lectures given by Christopher Pegge. In 1808, William
Buckland obtained his MA, became a fellow in the college he
attended, and was even ordained as a priest that same year.
Career
During the years 1808 to 1812, William Buckland went on
numerous geological excursions on horseback to different parts of
Scotland, England, Wales, and Ireland. He had taken his favourite
black mare on his journeys and examined sections of strata. He
even took home specimen for research purposes during those
excursions.
John Kidd resigned from his post as the Reader of Mineralogy, and
it was William Buckland who became his successor. He had a
colourful personality which he let shine during his lectures, and
that gained him even more students. Apart from being a well-loved
lecturer of mineralogy, he had also contributed as a curator of sorts
of the Old Ashmolean building. He even added his private
collection of fossils and rocks which he had kept in his old room
back in Corpus Christi College.
In 1818, he was able to persuade the Prince Regent to bestow him a
second reading, and it was Geology. During that time, his studies
had kept him very busy and he was involved in justifying the
inclusion of geology while keeping in line with the biblical
accounts of Creation as well as the Noachian flood. During his
days, fossils of animals were believed to be from the great deluge
and he had spent a lot of time understanding the timeline between
Click here to go at the top
3

06-01-2017

the great flood and the existence of the animals whose fossils he
had been examining.
On January 18, 1823, William Buckland discovered a skeleton
which he had then named as the Red Lady of Paviland since the
remains were found in the Paviland Cave. The name was because
he had first thought that the remains had been that of a prostitute
in the area, and his discovery had been the oldest and most
anatomically modern found in the U.K. While he had discovered
the strata in the same area where bones of mammoths and other
extinct animals had been, Buckland had shared his views with
Georges Cuvier who also believed that there were no humans who
lived the same time as extinct animals did. He then came to the
conclusion that the skeleton had probably been buried in a grave
made by earlier people. Years later and after carbon-data tests, the
Red Lady of Paviland was proven to be a male from around
33,000 years ago.
There was a time when Buckland had taken great interest in the
theory of Louis Agassiz and in 1938, he had a trip to Switzerland to
meet Agassiz himself. In 1840, these two scientists found evidence
of former glaciation. In the same year, Buckland became the
Geological Societys president once more and despite the hostile
reaction to the theory he had proposed, he had already been
convinced that glaciation was the origin of many of the surface
deposits which were in Britain then.
Personal Life
In December of 1825 when he had also accepted the Stoke of
Charity in Hampshire, he married Mary Morland. While she had
been only 28 then, she already had her own collection of fossils and
had even contributed to the works of both Buckland and Cuvier.
They had a shared passion for geology, and even their honeymoon
tour had destinations only geology lovers would plan on going to.
They had nine children, but only 5 survived to adulthood.
In 1850, he was afflicted with a disease which had greatly disabled
him and lead to his death six years later. From post-mortem
findings, there was a tubercular infection which spread to his
Click here to go at the top
4

06-01-2017

brain. Interestingly, the plot which had been reserved for his grave
had a Jurassic limestone which needed to be blown up before
proper excavation could be done and this was seen as a kid of final
jest from the geologist.

NEWS UPDATE

Brain protein predicts recovery time following

concussion: (06th January, 2017)

Elevated levels of the brain protein tau following concussion are

associated with a longer recovery period and may serve as a marker
to help physicians determine an athlete's readiness to return to
play, report investigators.

Study characterizes key molecular tool in DNA

repair enzymes: (06th January, 2017)
Oxidative damage to a cell's DNA is constant and destructive and a
complex suite of enzymes have evolved to repair and maintain it.
In an important new step in teasing out these complex processes,
an enzyme component known as Zf-GRF, which is highly
conserved in several enzymes and across species, has been shown
to be a key molecular tools that binds and orients repair enzymes
to DNA.

New treatment for a rare form of encephalitis:

(06th January, 2017)

Anti-NMDA receptor encephalitis is an inflammatory disease that

affects the central nervous system. It is a rare autoimmune disease
that results in the body producing antibodies against the NMDA
receptor, a protein that plays an important role in signal
transduction in the brain. Using a new treatment regimen,
researchers have recorded significant progress in treating the
disease, including in patients who did not previously respond to
treatment.

Click here to go at the top

5

06-01-2017

Tailored organoid may help unravel

response mystery: (06th January, 2017)

immune

Researchers report on the use of biomaterials-based organoids in

an attempt to reproduce immune-system events and gain a better
understanding of B cells.

Unexpected role for epigenetic

cancer: (06th January, 2017)

enzymes

in

A new study focused on a family of enzymes known as KDM5

that have been shown in previous studies to be involved in
cancer cell growth and spreading.

Time-restricted feeding study shows promise in

helping people shed body fat: (06th January,
2017)

For the first time in humans, it has been reported that eating early
in the day lessens daily swings in hunger and changes the 24-hour
pattern of fat oxidation and energy metabolism, which may aid in
weight loss.

New research describes how bacteria resists

'last-resort' antibiotic: (06th January, 2017)
An international research team has provided the first clues to
understand how the mcr-1 gene protects bacteria from colistin -- a
'last resort' antibiotic used to treat life-threatening bacterial
infections that do not respond to other treatment options.

Preventing mortality after myocardial infarction:

(05th January, 2017)
A new study is aiming to determine the optimal amount of blood
to transfuse in anemic patients who have suffered a myocardial
infarction.

Scientists
crack
the
structure
machinery: (05th January, 2017)

of

HIV

Click here to go at the top

6

06-01-2017

Antiviral therapy could be improved with newly uncovered

atomic-level details of the structure of HIV machinery, report
researchers.
For detail mail to editor

KNOWLEDGE BASED ARTICLE

FDA approves first drug for spinal muscular

atrophy
Atrophy is the partial or complete wasting away of a part of the
body. Causes of atrophy include mutations (which can destroy the
gene to build up the organ), poor nourishment, poor circulation,
loss of hormonal support, loss of nerve supply to the target organ,
excessive amount of apoptosis of cells, and disuse or lack
of exercise or disease intrinsic to the tissue itself. In medical
practice, hormonal and nerve inputs that maintain an organ or
body part are said to have trophic effects. A diminished muscular
trophic condition is designated as atrophy. The U.S. Food and
Drug Administration approved Spinraza (nusinersen), the first
drug approved to treat children and adults with spinal muscular
atrophy (SMA), a rare and often fatal genetic disease affecting
muscle strength and movement. Spinraza is an injection
administered into the fluid surrounding the spinal cord.
There has been a long-standing need for a treatment for spinal
muscular atrophy, the most common genetic cause of death in
infants, and a disease that can affect people at any stage of life,
said Billy Dunn, M.D., director of the Division of Neurology
Products in the FDAs Center for Drug Evaluation and Research.
As shown by our suggestion to the sponsor to analyze the results
of the study earlier than planned, the FDA is committed to
assisting with the development and approval of safe and effective
drugs for rare diseases and we worked hard to review this
Click here to go at the top
7

06-01-2017

application quickly; we could not be more pleased to have the first

approved treatment for this debilitating disease.
SMA is a hereditary disease that causes weakness and muscle
wasting because of the loss of lower motor neurons controlling
movement. There is wide variability in age of onset, symptoms and
rate of progression. Spinraza is approved for use across the range of
spinal muscular atrophy patients.
The FDA worked closely with the sponsor during development to
help design and implement the analysis upon which this approval
was based. The efficacy of Spinraza was demonstrated in a clinical
trial in 121 patients with infantile-onset SMA who were diagnosed
before 6 months of age and who were less than 7 months old at the
time of their first dose. Patients were randomized to receive an
injection of Spinraza, into the fluid surrounding the spinal cord, or
undergo a mock procedure without drug injection (a skin prick).
Twice the number of patients received Spinraza compared to those
who underwent the mock procedure. The trial assessed the
percentage of patients with improvement in motor milestones,
such as head control, sitting, ability to kick in supine position,
rolling, crawling, standing and walking.
The FDA asked the sponsor to conduct an interim analysis as a
way to evaluate the study results as early as possible; 82 of 121
patients were eligible for this analysis. Forty percent of patients
treated with Spinraza achieved improvement in motor milestones
as defined in the study, whereas none of the control patients did.
Additional open-label uncontrolled clinical studies were
conducted in symptomatic patients who ranged in age from 30
days to 15 years at the time of the first dose, and in presymptomatic
patients who ranged in age from 8 days to 42 days at the time of
first dose. These studies lacked control groups and therefore were
more difficult to interpret than the controlled study, but the
findings appeared generally supportive of the clinical efficacy
demonstrated in the controlled clinical trial in infantile-onset
patients.
Click here to go at the top
8

06-01-2017

The most common side effects found in participants in the clinical

trials on Spinraza were upper respiratory infection, lower
respiratory infection and constipation. Warnings and precautions
include low blood platelet count and toxicity to the kidneys (renal
toxicity). Toxicity in the nervous system (neurotoxicity) was
observed in animal studies.
The
FDA
granted
this
application fast
track
designation and priority review. The drug also received orphan
drug designation, which provides incentives to assist and
encourage the development of drugs for rare diseases.
The sponsor is receiving a rare pediatric disease priority review
voucher under a program intended to encourage development of
new drugs and biologics for the prevention and treatment of rare
pediatric diseases. A voucher can be redeemed by a sponsor at a
later date to receive priority review of a subsequent marketing
application for a different product. This is the eighth rare pediatric
disease priority review voucher issued by the FDA since the
program began.
Spinraza is marketed by Biogen of Cambridge, Massachusetts and
was developed by Ionis Pharmaceuticals of Carlsbad, California.
The FDA, an agency within the U.S. Department of Health and
Human Services, protects the public health by assuring the safety,
effectiveness, and security of human and veterinary drugs, vaccines
and other biological products for human use, and medical devices.
The agency also is responsible for the safety and security of our
nations food supply, cosmetics, dietary supplements, products
that give off electronic radiation, and for regulating tobacco
products.
Jeenatara Begum
Assistant Professor
GNIPST

Click here to go at the top

9

06-01-2017

DISEASE RELATED BREAKING NEWS

Human infection with avian influenza A(H7N9)

virus China: (03rd January, 2017)

On 30 December 2016, the Department of Health, Hong Kong

Special Administrative Region (SAR) notified WHO of a case of
laboratory-confirmed human infection with avian influenza
A(H7N9) virus.
Read more

UPCOMING EVENTS

3rd Three days Workshop on Statistical Methods in Biomedical

Research in Collaboration with National Institute of Medical

Statistics, New Delhi will be held on 4th to 6th January, 2017.

DRUGS UPDATES

Adamas Announces U.S. FDA Acceptance of

ADS-5102 New Drug Application for the
Treatment of Levodopa-induced Dyskinesia in
Patients with Parkinson's Disease: (06th January,
2017)

Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced that

the U.S. Food and Drug Administration (FDA) has accepted for
review the New Drug Application (NDA) for ADS-5102
(amantadine hydrochloride) extended-release capsules, for the
treatment of levodopa-induced dyskinesia (LID) in patients with
Parkinson's disease. The ADS-5102 application has been given a
Prescription Drug User Fee Act (PDUFA) target action date of
August 24, 2017.
Read more

Click here to go at the top

10

06-01-2017

CAMPUS NEWS
NBA Accreditation:
NBA has accreditated GNIPST.
Debate competition:
On 19th November, 2016 our student Pratik Nandy and Dippoman
Guha was participated in All India University debate Competition
organized by Calcutta Debate Circle.
International seminar 2016:
International seminar on Global Advancement in Pharmaceutical
research and startup organized by GNIPST in collaboration with
IPGA was held on 22nd October, 2016 at GNIPST auditorium.
NBA visit:
The experts of National Board of Accreditation or NBA will be
going to visit GNIPST on 24th September and 25th September,
2016.
Freshers welcome programme:
On 12th September GNIPST organized the Freshers welcome
programme Kulrav 2k16.
GNIPST Football Match 2016:
On 31st August and 1st September GNIPST sports club organized a
football match. The winner of the football match was B.Pharm 3rd
year.
Recent Trends in Pharmaceutical Research:
A Science Awareness Programme comprising of seminar on
Recent Trends in Pharmaceutical Research was organized by
GNIPST in collaboration with National Academy of Science India
(NASI) on 30th august, 2016 from 2 pm to 4.30 pm at GNIPST
auditorium. Plantation programme was also organized by Eco club.
Dr. Hemanta Kumar Majumder, gave his valuable lecture on
Modern Biology & its Evolution and Dr. Pijush K Das delivered
Click here to go at the top
11

06-01-2017

his lecture on Site specific Drug Targeting Magic Bullet

approach.
World Photography Day celebration:
On 19th August 2016 GNIPST celebrated World Photography Day
at Dakhineswar.
Friendly Football Match:
On 15th August 2016 GNIPST organised a friendly football match
with Alumni members.
Farewell 2016:
On 25th May 2016 GNIPST celebrated the farewell programme for
the final year students. Best of luck to all final year students for
their future life.
ALUMNI MEMBERS 2016:
Congratulations to new Alumni Members of GNIPST.
Placement Record 2016:
SL
NO

COMPANY NAME

NUMBER OF
NUMBER OF
STUDENT
STUDENT
APPEARED/APPLIED SELECTED
64
7

JOB
PROFILE

DR. LAL PATH LAB

APOLLO
PHARMACY

36

25

ABBOTT INDIA

74

03

HETERO DRUGS

18

Production,
QC and QA

ERIS LIFE SCIENCES

01

18 (Waiting
for final
interview)
01 (Joined)

JUPITER
PHARMACEUTICALS

05

01 (Joined)

Production,
QC and QA

GOVT PHARMACIST

4 (Joined)

Hospital
Pharmacist

Sales,
Marketing and
office assistant
Hospital and
retail chain
pharmacist
Sales and
Marketing

Sales and
Marketing

Click here to go at the top

12

06-01-2017
8

ALCHEMIST EYE
HOSPITAL

21

10

OPTIVAL HEALTH
SOLUTIONS PVT.
LTD. (MEDPLUS)
NESTLE INDIA LTD

2 (Waiting for
final
interview)
21

08

02

11

LUPIN

01

01

12

GSK
PHARMACEUTICAL
LTD
OAK
PHARMACEUTICAL

05

02 (1 of them
already joined)

Sales and
Marketing

06

02 (Joined)

Sales and
Marketing

13

Hospital
Pharmacist
Community
Pharmacist
Nutrition
Officer
Trainee
Sales and
Marketing

IPA Bengal Pharma & Healthcare trust scholarship 2016:

Congratulations to Rudradip Das, student of B.Pharm 3rd year has

been awarded IPA Bengal Pharma & Healthcare trust scholarship
2016.
Accreditation by NAAC:
SL.
NAME
OF
STATE
CGPA(out
GRADE
NO.
THE
of scale 4)
INSTITUTE
01
Guru
Nanak
West
2.70
B
Institute
of
Bengal
Pharmaceutical
Science
And
Technology,
Kolkata-700114

GPAT 2016 Result:

The following B.Pharm. final year students have qualified, GPAT2016. We congratulate them all.
Aishika Datta
Mainak Chatterjee
Click here to go at the top
13

06-01-2017

Indira Saha
Priyanka De
Aheli Mukherjee
Soumya Guha
Debanjana Das
Debalina Datta
Evana Patra
Himadrija Chatterjee
IRIS 2016:
GNIPST organized colllege fest IRIS 2016 from 11th to 13th March,
2016.
Result of different events:
Intracollege Quiz competition:
1st: Arani Roy and Dipayan Nath
2nd: Bhaskar Singha and Pratik Nandi
Intracollege Painting competition:
1st: Swagata Paul
2nd: Aviraj Pathak
3rd: Dippyoman Guha
Group Dance Competition:
Karma Group
Intercollege Solo Dance Competition:
1st : Monodipa Ghosh
2nd: Aditya Paul (NIT)
Antaksari Competition:
1st: Sunanda and Aparupa
2nd: Meghna and Joyita
3rd: Arpita and Pami
Intercollege Solo Singing Competition:
1st: Arpita Sarkar
2nd: Arvind Raj (Sudhir Chandra College)
Click here to go at the top
14

06-01-2017

3rd: Priyam Mondal (Supreme College)

Intercollege Band Competition:
1st: D Errors
2nd: Mukti
3rd: GNIPST band
Fashion:
Best Male: Md. Nadeem Shah
Best Female: Sweta
Best Couple: Md. Nadeem Shah and Susmita Kar
Blood donation Camp 2016:
On 4th March 2016 Social Service club and Alumni Association
of GNIPST organized a Blood donation camp in association with
Association of voluntary Blood Donars, West Bengal.
Reminiscence & 1st Alumni meet 2016:
On 28th February 2016 GNIPST organized the Reunion programme
Reminiscence & 1st Alumni meet 2016.
National Assessment and Accreditation Council (NAAC):
A NAAC peer team completed a three-day inspection (17th
February to 19th February, 2016) of GNIPST to evaluate its
academic credibility and infrastructure on Friday.
Saraswati Puja 2016:
On 13th February 2016 the students of GNIPST celebrated
Saraswati Puja at GNIPST campus.

Click here to go at the top

15

06-01-2017

STUDENTS SECTION
WHO CAN ANS WER FIRS T????
Identify the Person

Answer of Previous Issues Image:

Isaac Ashimov

Send

your
thoughts/
Quiz/Puzzles/games/write-ups or any other
contributions for Students Section& answers
of this Section at gnipstbulletin@gmail.com
EDITORS NOTE
It is a great pleasure for me to publish the 4th issue of 62th Volume
of GNIPST BULLETIN. All the followers of GNIPST BULLETIN
are able to avail the bulletin through facebook account GNIPST
bulletin I am very much thankful to all the GNIPST members and
readers who are giving their valuable comments, encouragements
and supports. I am also thankful to Dr. Abhijit Sengupta, Director
of GNIPST for his valuable advice and encouragement. Special
thanks to Dr. Prerona Saha, Mr. Debabrata Ghosh Dastidar
and Mr. Soumya Bhattacharya for their kind co-operation and
technical supports. Thank you Mr. Soumya Bhattacharya for the
Click here to go at the top
16

06-01-2017

questionnaires of the student section. An important part of the

improvement of the bulletin is the contribution of the readers. You
are invited to send in your write ups, notes, critiques or any kind of
contribution for the forthcoming special and regular issue.
ARCHIVE
OTHERS:
AICTE has sanctioned a release of grant under Research
Promotion Scheme (RPS) during the financial year 2012-13to
GNIPST as per the details below:
a. Beneficiary Institution: Guru Nanak Institution of Pharmaceutical
Science & Technology.
b. Principal Investigator: Dr. LopamudraDutta.
c. Grant-in-aid sanctioned:Rs. 16,25000/- only
d. Approved duration: 3 years
e. Title of the project: Screening and identification of potential
medicinal plant of Purulia & Bankura districts of West Bengal
with respect to diseases such as diabetes, rheumatism, Jaundice,
hypertension and developing biotechnological tools for enhancing
bioactive molecules in these plants.

Activity Clubs of GNIPST:

Name of Club
CULTURAL
DEBATE AND EXTEMPORE
ECO
LITERARY AND PAINTING
PHOTOGRAPHY

Member Faculty
Ms. Priyanka Ray
Mr. Soumya Bhattacharya
Ms. Sumana Roy
Ms. Jeenatara Begum
Ms. Sanchari Bhattacharya and
Mr. Abir Koley
SCIENCE AND INNOVATIVE Mr. Samrat Bose
MODELLING
SOCIAL SERVICES
Dr. Asis Bala
SPORTS
Mr. Debabrata GhoshDastidar
Click here to go at the top
17